Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-12-13
2010-02-02
Nguyen, Bao-Thuy L (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S091200, C435S805000, C435S810000, C436S501000, C436S514000, C436S518000
Reexamination Certificate
active
07655416
ABSTRACT:
The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the risk of suffering from a cardiovascular complication, particularly heart disease or acute coronary syndrome, as a consequence of cardiotoxic medication, in particular chemotherapeutics, including anthracyclines. In particular, the invention relates to a method for diagnosing the risk of a patient who is going to receive cardiotoxic medication of suffering from a cardiovascular complication as a consequence of the cardiotoxic medication, comprising the steps of (a) taking a body fluid or tissue sample, and (b) measuring, preferably in vitro, the level of a cardiac hormone. Preferred cardiac hormones in the context of the present invention are ANP, NT-proANP, BNP, and NT-proBNP.
REFERENCES:
patent: 5744305 (1998-04-01), Fodor et al.
patent: 02/083913 (2002-10-01), None
patent: 02/089657 (2002-11-01), None
patent: WO 02/083913 (2008-10-01), None
Neri et al., Int. J. Clin. Pham Re. 1991; 11:75-81.
Okumura et al., Acta Haematol 2000; 104:158-163.
Nousiainen et al., Eur. J. Haematol. 1999; 62:135-141.
Von Hoff et al., Annals of Internal Medicine. 1979; 81:710-77.
Nousiainen et al., Journal of Internal Medicine. 2002; 251:228-234.
Ala-Kopsala, M, et al., “Molecular Heterogenity Has a Major Impact on the Measurement of Circulating N-Terminal Fragments of A- and B- Type Natriuretic Peptides,” Clinical Chemstry 50:9, 1576-1588 (2004).
Barbaro, G. et al., “Cardiovascular Manifestations of HIV Infection,” Circulation, vol. 166 (1996) 1420-1425.
Bonow, R. et al., “New Insights Into the Cardiac Natriuretic Peptides,” Circulation 93:11, Jun. 1, 1996, 1946-1950.
Meinardi, M.T. et al., “Prospective Evaluation of Early Cardiac Damage Induced by Epirubicin-Containing Adjuvant Chemotherapy and Locoregional Radiotherapy in Breast Cancer Patients,” Journal of Clinical Oncology 19:10 (May 15, 2001) 2746-2753.
Mohideen, M. R. et al., “Brain Natriuretic Peptide is more than a Marker,” Ceylon Medical Journal 47:3, Sep. 2002, 81-82.
Mueller, T. et al., “Comparrison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NT-proBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart Disease,” Clinical Chemistry 49, No. 6, 2003, 976-979.
Nielsen, L et al., “N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea,” The European Journal of Heart Failure 6 (2004) 63-70.
Nolan, J. et al., “Suspension array technology: evolution of the flat-array paradigm,” Trends in Biotechnology 20:1 (Jan. 2002) 9-12.
Okumura, H. et al., “Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity,” Acta Haematol 2000; 104:158-163.
Sundsfjord, J. et al., “Identification and Plasma Concentrations of the N-Terminal Fragment of Proatrial Natriuretic Factor in Man,” Journal of Endocrinology and Metabolism 66:3, 1988, 605-610.
Suzuki, T. et al., “Elevated B-Type Natriuretic Peptide Levels After Anthracycline Administration,” American Heart Journal 136:2, (1998) 362-363.
Tsekoura, D. et al., “Brain Natriuretic Peptide,” Hellenic J. Cardiol 44:266-270 (2003).
Hess Georg
Horsch Andrea
Amick Marilyn
Nguyen Bao-Thuy L
Roche Diagnositcs Operations, Inc.
Roche Diagnostics Operations Inc.
LandOfFree
Diagnosing risk of cardiovascular complications using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosing risk of cardiovascular complications using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosing risk of cardiovascular complications using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150442